VolitionRX
VNRX
About: VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Employees: 48
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
52% more capital invested
Capital invested by funds: $12M [Q1] → $18.2M (+$6.25M) [Q2]
16% more funds holding
Funds holding: 25 [Q1] → 29 (+4) [Q2]
1.39% more ownership
Funds ownership: 21.89% [Q1] → 23.28% (+1.4%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Financial journalist opinion
Based on 5 articles about VNRX published over the past 30 days
